ORASURE TECHNOLOGIES, INC APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition
ORASURE TECHNOLOGIES, INC (OSUR) reported APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition of $1.16 million for the 12-month period ending 2019-12-31, per its 10-K filed 2020-03-02.
Discontinued › Shareholders' Equity › APIC, Share-Based Payment Arrangement, Increase for Cost Recognition
us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition · last filed 2020-03-02
- ORASURE TECHNOLOGIES, INC apic, share-based payment arrangement, option, increase for cost recognition for the quarter ending 2019-12-31 was $267.00K.
- ORASURE TECHNOLOGIES, INC apic, share-based payment arrangement, option, increase for cost recognition for the quarter ending 2019-09-30 was $259.00K, a 27.86% decline year-over-year.
- ORASURE TECHNOLOGIES, INC apic, share-based payment arrangement, option, increase for cost recognition for the quarter ending 2019-06-30 was $311.00K, a 34.53% decline year-over-year.
- ORASURE TECHNOLOGIES, INC apic, share-based payment arrangement, option, increase for cost recognition for the quarter ending 2019-03-31 was $324.00K, a 64.00% decline year-over-year.
- ORASURE TECHNOLOGIES, INC apic, share-based payment arrangement, option, increase for cost recognition for fiscal 2019 was $1.16M, a 46.32% decline from fiscal 2018.
- ORASURE TECHNOLOGIES, INC apic, share-based payment arrangement, option, increase for cost recognition for fiscal 2018 was $2.16M, a 5.77% increase from fiscal 2017.
- ORASURE TECHNOLOGIES, INC apic, share-based payment arrangement, option, increase for cost recognition for fiscal 2017 was $2.04M, a 24.01% decline from fiscal 2016.
- ORASURE TECHNOLOGIES, INC apic, share-based payment arrangement, option, increase for cost recognition for fiscal 2016 was $2.69M, a 20.92% decline from fiscal 2015.
| Period end | APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition 9 month | APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition 12 month | APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition 12 month as first filed |
|---|---|---|---|---|---|
| 2019-12-31 | $267.00K derived: 10-K 12 month − 3 quarters · filed 2020-03-02 | $526.00K derived: sum of 2 quarters · filed 2020-03-02 | $837.00K derived: sum of 3 quarters · filed 2020-03-02 | $1.16M 10-K · filed 2020-03-02 | |
| 2019-09-30 | $259.00K 10-Q · filed 2019-11-08 | $570.00K derived: sum of 2 quarters · filed 2019-11-08 | $894.00K derived: sum of 3 quarters · filed 2019-11-08 | ||
| 2019-06-30 | $311.00K 10-Q · filed 2019-11-08 | $635.00K derived: sum of 2 quarters · filed 2019-11-08 | |||
| 2019-03-31 | $324.00K 10-Q · filed 2019-11-08 | ||||
| 2018-12-31 | $2.16M 10-K · filed 2020-03-02 | ||||
| 2018-09-30 | $359.00K 10-Q · filed 2019-11-08 | $834.00K derived: sum of 2 quarters · filed 2019-11-08 | $1.73M derived: sum of 3 quarters · filed 2019-11-08 | ||
| 2018-06-30 | $475.00K 10-Q · filed 2019-11-08 | $1.38M derived: sum of 2 quarters · filed 2019-11-08 | |||
| 2018-03-31 | $900.00K 10-Q · filed 2019-11-08 | ||||
| 2017-12-31 | $2.04M 10-K · filed 2020-03-02 | ||||
| 2016-12-31 | $2.69M 10-K · filed 2019-02-28 | ||||
| 2015-12-31 | $3.40M 10-K · filed 2018-02-28 | ||||
| 2014-12-31 | $3.08M 10-K · filed 2017-03-14 | ||||
| 2013-12-31 | $2.69M 10-K · filed 2016-03-14 | ||||
| 2012-12-31 | $2.26M 10-K · filed 2015-03-12 | ||||
| 2011-12-31 | $1.58M 10-K · filed 2014-03-14 | $1.58M 10-K · filed 2012-03-14 | |||
| 2010-12-31 | $884.00K 10-K · filed 2013-03-13 | $883.61K 10-K · filed 2012-03-14 | |||
| 2009-12-31 | $1.32M 10-K · filed 2012-03-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Anika Therapeutics, Inc. (ANIK) | United States | $0.272B | -51.71 |
| Cytosorbents Corp (CTSO) | United States | $0.274B | -1.29 |
| TriSalus Life Sciences, Inc. (TLSI) | United States | $0.283B | -9.92 |
| InfuSystem Holdings, Inc (INFU) | United States | $0.253B | 22.52 |
| Mobia Medical, Inc. (MOBI) | United States | $0.293B | |
| TREACE MEDICAL CONCEPTS, INC. (TMCI) | United States | $0.297B | -4.32 |
| UTAH MEDICAL PRODUCTS INC (UTMD) | United States | $0.238B | 20.93 |
| PRO DEX INC (PDEX) | United States | $0.234B | 13.64 |
| Embecta Corp. (EMBC) | United States | $0.319B | 2.10 |
| Neuronetics, Inc. (STIM) | United States | $0.216B | -3.25 |